Form 8-K

8-K — BioXcel Therapeutics, Inc.

Accession: 0001104659-26-080501

Filed: 2026-07-06

Period: 2026-07-06

CIK: 0001720893

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — tm2619779d1_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2619779d1_ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2619779d1_8k.htm · Sequence: 1

false

0001720893

2026-07-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 6, 2026

BioXcel

Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-38410

82-1386754

(State

or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification No.)

555

Long Wharf Drive

New

Haven, CT 06511

(Address of principal executive offices, including

Zip Code)

(475)

238-6837

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed

since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

Stock, par value $0.001

BTAI

The Nasdaq

Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01

Entry into a Material Definitive Agreement.

On July 3, 2026, BioXcel Therapeutics, Inc. (the “Company”)

entered into the Tenth Amendment to Credit Agreement and Guaranty (the “Tenth Amendment”), which amended the Credit Agreement

and Guaranty, dated April 19, 2022, as amended (the “Credit Agreement”), by and among the Company, as the borrower, certain

subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the “Lenders”),

and Oaktree Fund Administration LLC, as administrative agent.

Pursuant

to the Tenth Amendment, the Lenders agreed to (i) payment in kind of accrued and unpaid interest through and including June 30,

2026, by capitalizing and adding such interest to the outstanding principal amount of the Loans as of such date, (ii) defer the

payment of principal that was originally due on June 30, 2026 until July 31, 2026, at which point the Company is

obligated to make a payment of $9,016,914.47 (constituting the principal and interest that were due and payable on June 30,

2026) plus all accrued interest and fees on such amount through and including July 31, 2026) and (iii) reduce the Credit

Agreement’s minimum liquidity covenant to require minimum cash liquidity of $7.5 million (instead of $12.5 million).

In addition, pursuant to the Tenth Amendment, among other things:

· The

Company is required to, on or prior to July 31, 2026, enter into definitive agreements with respect to one or more transactions acceptable

to Lenders that (A) would result in the repayment of all loan and other obligations under the Credit Agreement or (B) is an alternative

capital solutions transaction on terms and conditions acceptable to the Lenders.

· The

Company agreed to permit any and all transfers or assignments of all or any portion of the loans, commitments, claims or other rights,

interests or obligations of any Lender under or in respect of the Credit Agreement to any third party. In addition, the Company

agreed to waive or otherwise release any and all restrictions contained in any contract between the Company and a third party on such

third party’s ability to receive such assignments or transfers.

· The

Company agreed to establish and maintain a strategic process committee of its board of directors,

which committee shall be comprised solely of David Mack (and/or such other independent director

acceptable to the Lenders and that is not a member of the Board as of the Tenth Amendment

Effective Date), that will have the full and exclusive authority to evaluate, negotiate,

oversee, coordinate and implement any sale, restructuring or other material transaction,

including any equity raise, sale or business combination transaction, out-of-court restructuring,

in-court restructuring, bankruptcy or insolvency filing or similar transaction and any other

matters or actions as may be necessary or advisable to effectuate any of the foregoing.

· The

Company agreed to certain additional reporting and information covenants, including a requirement to hold a weekly meeting with the Lenders

and the Company’s financial advisors, and a requirement to deliver to the Lenders a 13-week cash flow budget and financial report

on a bi-weekly basis. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate

budgeted amount of disbursements for the applicable period.

· The

Company agreed to certain additional negative covenants applicable following the Tenth

Amendment Effective Date, which, among other things, prohibit the Company from, subject to

limited exceptions, (i) making any dividend, distribution or repurchase with respect to its

equity interests, (ii) making any investments, (iii) disposing of or granting any license

in the Company’s assets, (iv) incurring or suffering to exist any indebtedness or liens,

and (v) becoming party to or bound by, or canceling, terminating, modifying or amending in

any material respect, or waiving any material rights under any material contract.

· Through

July 31, 2026, the Company is prohibited from entering into, terminating, or otherwise modifying

any compensation arrangement with its directors, officers or employees, or making any non-ordinary

course payments to, or materially increasing the compensation or benefits of, such persons.

In connection with the Tenth Amendment, the Company paid to the Lenders

a fee equal to 100 basis points (or 1.00%) of the principal amount of the Loans outstanding as of the effective date of the Tenth Amendment,

which was paid in kind by adding such amount to the outstanding principal amount of the Loans on the effective date of the Tenth Amendment.

The foregoing summary of the Tenth Amendment is qualified in its entirety

by the complete text of such agreement, a copy of which is filed hereto as Exhibits 10.1.

Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits.

Ex. No. Description

10.1 Tenth Amendment to Credit Agreement and Guaranty, dated July 3, 2026.

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Date: July 6, 2026

BIOXCEL THERAPEUTICS, INC.

/s/ Richard

Steinhart

By:

Richard Steinhart

Title:

Chief Financial Officer

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2619779d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

TENTH AMENDMENT

TO Credit agreement AND guaranty

This Tenth Amendment to Credit

Agreement and Guaranty (this “Amendment”) is made as of July 3, 2026, by and among BIOXCEL THERAPEUTICS, INC.,

a Delaware corporation (the “Borrower”), the lenders party hereto (collectively, the “Lenders”

and individually, a “Lender”), and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent on behalf of the

Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).

WHEREAS, the Borrower, the

Administrative Agent and the Lenders previously entered into that certain Credit Agreement and Guaranty, dated as of April 19, 2022 (including

the exhibits and other attachments thereto, as amended as of November 13, 2023, December 5, 2023, February 12, 2024, March 20, 2024,

November 21, 2024, December 6, 2024, March 4, 2025, March 12, 2025, April 22, 2025, and March 27, 2026 (the “Existing Credit

Agreement”, and as further amended by this Amendment, the “Credit Agreement”);

WHEREAS, the Borrower, the

Administrative Agent and the Lenders have agreed to amend the Existing Credit Agreement on the terms and subject to the conditions set

forth herein.

NOW, THEREFORE, for and in

consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged

by the parties hereto, each of the Borrower, the Administrative Agent and the Lenders party hereto hereby covenant and agree as follows:

1. Definitions.

Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned

to such terms in the Existing Credit Agreement.

2. Amendments

to the Existing Credit Agreement. Subject to the satisfaction of the conditions precedent

specified in Section 5 hereof:

(a) A

new definition of “Tenth Amendment” is added to the Credit Agreement in appropriate

alphabetical order as follows:

“Tenth Amendment” means the Tenth

Amendment to this Agreement, dated as of July 3, 2026.

(b) A

new definition of “Tenth Amendment Effective Date” is added to the Credit Agreement

in appropriate alphabetical order as follows:

“Tenth Amendment Effective

Date” means the date all of the conditions precedent set forth in Section 5 of the Tenth Amendment have been satisfied.

definition of “Minimum Liquidity Amount” in the Credit Agreement is hereby amended

and restated in its entirety as set forth below:

Minimum Liquidity

Amount” means (i) prior to consummation of the Fifth Amendment Equity Raise One, $25,000,000, (ii) upon consummation of

the Fifth Amendment Equity Raise One to but excluding March 31, 2025, $7,500,000, (ii) from March 31, 2025 to but excluding January 1,

2026, $10,000,000, (iii) from and after January 1, 2026 to but excluding March 31, 2026, $15,000,000, (iv) from and after March 31, 2026

to but excluding the Tenth Amendment Effective Date, $12,500,000, and (v) from and after the Tenth Amendment Effective Date, $7,500,000.

(d) The

Payment Date scheduled to occur on June 30, 2026 shall be deferred to July 31, 2026 and the

Borrower shall make a payment on such date of $9,016,914.47 (constituting the principal and

interest that were due and payable on June 30, 2026) plus all accrued interest and

fees on such amount through and including July 31, 2026.

3. Reaffirmation

of Loan Documents. Except as otherwise expressly provided herein, the parties hereto

agree that all terms and conditions of the Existing Credit Agreement and the other Loan Documents

remain in full force and effect. The Borrower hereby confirms that the Security Documents

and all of the Collateral described therein do, and shall continue to, secure the payment

in full and performance of all of the Obligations.

4. Other

Agreements.

(a) June

30 Interest. All accrued and unpaid interest on the Loans due through and including June

30, 2026 shall be paid in kind on the Tenth Amendment Effective Date by capitalizing and

adding such interest to the outstanding principal amount of the Loans as of such date.

(b) Amendment

Fee. On the Tenth Amendment Effective Date, the Borrower shall pay to the Lenders a fee

equal to 100 basis points (or 1.00%) of the principal amount of the Loans outstanding as

of the Tenth Amendment Effective Date (after giving effect to the payment in kind of the

accrued and unpaid interest pursuant to Section 4(a) hereof), which will be paid in kind

by adding such amount to the outstanding principal amount of the Loans.

Milestone. On or prior to July 31, 2026, the Obligors shall have entered into definitive

agreements with respect to one or more transactions, in form and substance acceptable to

the Majority Lenders in their sole discretion, that (A) would result in the indefeasible

payment in full in cash of all Obligations under the Loan Documents or (B) is an alternative

capital solutions transaction on terms and conditions acceptable to the Majority Lenders

in all respects, in their sole and absolute discretion, including, in each case, with respect

to the certainty and timing of closing and the likelihood of obtaining any required shareholder,

regulatory, court or other approvals, as applicable (any such transaction, an “Acceptable

Transaction”).

-2-

(d) Transfer

Rights; Waiver of Restrictions.

(i) Waiver

and Release of Transfer Restrictions. Within one (1) business day following the Tenth

Amendment Effective Date, each Obligor shall waive, modify, terminate or otherwise release,

in form and substance reasonably satisfactory to the Majority Lenders, (i) any and all restrictions

(whether contained in any confidentiality agreement, any side letter, any organizational

document, or any other agreement, instrument or arrangement of any kind) on the ability of

any party to negotiate, solicit, market, enter into, or otherwise consummate a participation,

assignment, novation, acquisition or other transfer (each, a “Transfer”)

of all or any portion of the Loans, commitments, Claims or other rights, interests or obligations

of any Lender under or in respect of the Credit Agreement (the “Subject Interests”)

to such party, and (ii) any consent right, approval right, prior notice requirement, information

right, qualification or eligibility requirement, or any similar right, requirement or restriction,

in each case in favor of, exercisable by, or for the benefit of each Obligor in respect of

any such Transfer.

(ii) Free

Right to Transfer. Notwithstanding anything to the contrary contained in this Amendment,

the Credit Agreement, any other Loan Document or any other agreement, instrument or arrangement

(and regardless whether the Obligors have complied with clause (i) above within the time

period specified therein), the Obligors hereby agree that each Lender shall be permitted,

at any time and from time to time, in its sole discretion, to negotiate, solicit, market,

enter into, and consummate one or more Transfers of all or any portion of its Subject Interests

to any party, in each case without any notice to, or any consent, approval, acknowledgment

or other action of or by, the Obligors, and the Obligors hereby irrevocably waive any and

all such notice, consent, approval, acknowledgment and similar rights and requirements.

(iii) No

Future Restrictions. The Obligors agree that, from and after the Tenth Amendment Effective

Date, no Obligor shall, directly or indirectly, enter into, agree to, consent to, acquiesce

in, reinstate or otherwise become bound by any agreement, instrument, arrangement, amendment,

side letter, policy or other restriction (whether written or oral) that purports to restrict,

condition, limit, delay or impose any consent right, notice requirement, qualification, eligibility

requirement or other similar burden on the ability of any Lender to negotiate, solicit, market,

enter into or consummate any Transfer of all or any portion of the Subject Interests, or

that would otherwise be inconsistent with the rights of the Lenders set forth in this Section

4(d).

(e) Strategic

Process. Subject to the terms and conditions of Section 8.13 of the Credit Agreement,

the Borrower shall promptly deliver to the Lenders and the Administrative Agent copies of

all written presentations, decks, proposals, term sheets or other similar materials, including

drafts thereof, presented to the Borrower’s Board with respect to a transaction contemplated

by Section 4(c) hereof, which may be redacted, as necessary, to the extent that such

materials are subject to attorney-client or similar privilege and such privilege could reasonably

be expected to be lost or forfeited if the redacted content were disclosed. In addition,

the Borrower shall, and shall cause each of its Subsidiaries to, promptly (and in any event

within two (2) Business Days of receipt, making or occurrence thereof) provide the Lenders

and the Administrative Agent with written notice of, and copies of, all bona fide written

offers, proposals, indications of interest, letters of intent, term sheets or similar communications

(whether binding or non-binding) relating to any potential equity raise, any sale or business

combination transaction, or any recapitalization or restructuring transaction involving the

Borrower or any of its Subsidiaries.

-3-

(f) Strategic

Process Committee. The Obligors (i) shall not take any action to, directly or indirectly,

(x) dissolve the Strategic Process Committee (as defined below) or revoke or reduce the scope

of authority delegated to the Strategic Process Committee or (y) remove or replace any member

of the Strategic Process Committee without the prior written consent of the Majority Lenders,

and (ii) in the event a member of the Strategic Process Committee resigns or is unable to

continue to serve on the Strategic Process Committee, shall cause the prompt appointment

of a replacement director acceptable to the Majority Lenders. The terms and conditions of

Section 8.13 of the Credit Agreement shall not apply with respect to the Strategic Process

Committee.

(g) Weekly

Lender Meetings. The Borrower shall cause each of MERU and MTS Partners, each as a financial

advisor to the Borrower (each, a “Financial Advisor”), to attend (no more

than once per week) a telephonic (or by other electronic means) call (scheduled at a time

reasonably mutually acceptable to Financial Advisors and the applicable Lenders) between

each Financial Advisor, the Administrative Agent and the Lenders and their counsel to discuss

the financial affairs of the Obligors in reasonable detail, including the status of any strategic

transaction and the status of any definitive documents or court filings related to such strategic

transaction; provided that counsel for the Administrative Agent and/or the Lenders

shall be permitted to attend and participate in such meetings only to the extent such meetings

are attended by counsel for the Obligors.

(h) Reporting

Requirements.

(i) Financial

Condition. Commencing the first full calendar week after the date hereof, the Borrower

shall deliver to the Lenders and the Administrative Agent on the fifth Business Day of every

other calendar week (i) a 13-week cash flow budget of the Borrower and its Subsidiaries,

on a consolidated basis, covering the 13-week period after the week’s end of the week

in which such day occurs, which shall include a variance report showing all variances by

line-item from the amounts set forth in the budget for the prior Budget Variance Test Period,

as most recently updated, with an explanation for each material line-item variance; (ii)

a financial report with respect to the Obligors, including setting forth in reasonable detail

the accounts receivable and accounts payable of the Obligors; and (iii) any other information

as the Lenders may reasonably request in writing with respect to the financial affairs of

the Obligors. To the extent of any conflict between this Section 4(h)(i) and Section

8.01 of the Credit Agreement, this Section 4(h)(i) shall control.

-4-

(ii) Maximum

Variance. From and after the Tenth Amendment Effective Date, the variance in the aggregate

disbursements for a particular Budget Variance Test Period as compared to those set forth

in the budget for such period, as most recently updated, shall not exceed fifteen percent

(15%) of the aggregate disbursements budgeted for such period. To the extent of any conflict

between this Section 4(h)(ii) and Section 8.21 of the Credit Agreement, this Section

4(h)(ii) shall control.

(i) Restricted

Activities. Notwithstanding anything to the contrary in the Credit Agreement or any other

Loan Document, from and after the Tenth Amendment Effective Date, no Obligor shall, nor shall

any Obligor permit any of its Subsidiaries to, directly or indirectly, in each case other

than pursuant to an Acceptable Transaction consummated in accordance with Section 4(c)

hereof:

(i) make

any dividend or other distribution (whether in cash, Equity Interests or other property)

with respect to any Equity Interests of the Borrower or any of its Subsidiaries, or any payment

(whether in cash, Equity Interests or other property), including any sinking fund or similar

deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or

termination of any such Equity Interests of the Borrower or any of its Subsidiaries, or any

option, warrant or other right to acquire any such Equity Interests of the Borrower or any

of its Subsidiaries;

(ii) make

any loans, advances or capital contributions to, or investments in, any other Person, other

than in the ordinary course of business consistent with past practice;

(iii) incur,

transfer, sell, assign, contribute or otherwise convey any indebtedness of any Obligor or

any equity interests of any Obligor to any Excluded Subsidiary;

(iv) permit

any Subsidiary of any Obligor to cease to be a Wholly-Owned Subsidiary at all times;

(v) acquire,

sell, lease, pledge, dispose of, transfer, let lapse, license or encumber or authorize the

sale, pledge, disposition, transfer or encumbrance of any assets of the Borrower or any of

its Subsidiaries, other than in the ordinary course of business consistent with past practice

or as may be required by applicable Law;

(vi) grant

any license or sublicense of, or abandon, disclaim, dedicate to the public, permit to lapse,

sell, transfer, lease, assign or otherwise dispose of, or grant any security interest in

or to any Material Intellectual Property, clinical or non-clinical data, Regulatory Approvals

or any other Intellectual Property within the control of the Borrower or any of its Subsidiaries,

other than pursuant to one or more non-exclusive licenses of immaterial Intellectual Property

granted by the Borrower or any of its Subsidiaries in the ordinary course of business or

an Acceptable Transaction consummated in accordance with Section 4(c);

-5-

(vii) directly

or indirectly, (I) create, incur, assume or otherwise become or remain liable with respect

to any Indebtedness or issue any Equity Interests, (II) create, incur, assume or permit to

suffer to exist any Lien on or with respect to any property of any kind owned by it, whether

now owned or hereafter acquired, or any income or profits therefrom, (III) make or own any

Investment in any other Person, (IV) enter into any transaction of merger, consolidation

or amalgamation, or liquidate, wind up or dissolve themselves (or suffer any liquidation

or dissolution) or (V) convey, sell, lease or otherwise dispose of all or any part of its

property or assets or to otherwise engage in any other activity, in each case ((I) through

(IV)), that is undertaken in connection with or to facilitate a new financing incurred by

any subsidiary or affiliate of any Obligor (including a debtor-in-possession financing) or

to guarantee an existing financing in connection with a Liability Management Transaction.

“Liability Management Transaction” means any liability management transaction

including any refinancing, retirement, exchange, extension, repurchase, consent solicitation,

amendment, investment, asset transfer, designation, debt incurrence, restricted payment,

intercompany arrangement or otherwise that has the purpose or effect, directly or indirectly,

of (1) issuing debt that is contractually, structurally, effectively or temporally senior

(including as to lien priority or additional collateral) to any of the Obligations, or provides

additional collateral or guarantees not provided to the Lenders, (2) subordinating, releasing

or impairing the liens, guarantees, or payment rights supporting the Loans, or (3) otherwise

impairing the recovery prospects of the Lenders, or series of transactions related to the

foregoing; or

(viii) become

party to or bound by, or cancel, terminate, modify or amend in any material respect, or waive

any material rights under any material contract, in each case, except in the ordinary course

of business or consistent with past practice; provided that, for the avoidance of

doubt, nothing in this Section 4(i)(viii) shall be construed to waive, modify or otherwise

limit any restriction set forth in Section 9 of the Credit Agreement or any other Loan Document.

-6-

(j) Compensation

Arrangements. Notwithstanding anything to the contrary in the Credit Agreement or any

other Loan Document, unless the Majority Lenders agree in advance in writing, through and

including July 31, 2026, the Borrower shall not, and shall not permit any of its Subsidiaries

to, directly or indirectly (i) enter into, terminate, or otherwise modify any Compensation

Arrangement or (ii)(a) make any payment to any officer or employee of the Borrower or any

of its Subsidiaries outside of the ordinary course of business, (b) agree to, or incur, any

material increase in the compensation payable or to become payable to any officer or employee

of the Borrower or any of its Subsidiaries or (c) otherwise materially increase the benefits

of any such officer or employee. “Compensation Arrangement” means all

employment and severance agreements and policies, and all employment, wages, compensation,

and benefit plans and policies, workers’ compensation programs, savings plans, retirement

plans, deferred compensation plans, supplemental executive retirement plans, healthcare plans,

disability plans, severance benefit plans, incentive and retention plans, programs, and payments,

life and accidental death and dismemberment insurance plans and programs of the Borrower

and its Subsidiaries, and all amendments and modifications thereto, applicable to the employees,

former employees, retirees, and non-employee directors and managers of the Borrower or any

of its Subsidiaries, as applicable.

(k) Continued

Cooperation. Through and including July 31, 2026, the Obligors shall consider in good

faith any reasonable comments by the Lenders or any counterparty to a potential transaction

contemplated by Section 4(c), in each case with respect to any regulatory process

involving material assets of the Obligors.

5. Conditions

Precedent to Effectiveness. This Amendment shall be subject to the following conditions

precedent:

(a) This

Amendment shall have been duly executed and delivered to the Administrative Agent by the

Borrower and the Lenders, which constitute all of the Lenders under the Existing Credit Agreement;

(b) Each

of the representations and warranties in Section 6 of this Amendment, Section 7 of

the Credit Agreement and in the other Loan Documents shall be true, accurate and complete

in all material respects (unless such representations are already qualified by reference

to materiality, Material Adverse Effect or similar language, in which case such representations

and warranties shall be true and correct in all respects) on and as of the date hereof with

the same effect as though made on and as of such date, except to the extent such representations

and warranties expressly relate to an earlier date, in which case such representations and

warranties shall have been true and correct in all respects on and as of such earlier date;

the time of and after giving effect to this Amendment, no fact or condition exists that constitutes,

or with the passage of time, the giving of notice, or both, would constitute, a Default or

Event of Default; and

(d) the

Borrower shall have (i) established a committee of its Board (the “Strategic

Process Committee”) for the purposes of evaluating, negotiating, overseeing,

coordinating and implementing a strategic transaction or a series of strategic transactions,

including a proceeding under chapter 11 of the Bankruptcy Code, as well as restructuring,

sale, or recapitalization transactions, which committee shall be comprised solely of David

Mack (and/or such other independent director acceptable to the Majority Lenders), and (ii)

irrevocably delegated to the Strategic Process Committee the full and exclusive authority

to evaluate, negotiate, oversee, coordinate and implement (A) any sale, restructuring or

other material transaction relating to the Obligors, including any equity raise, sale or

business combination transaction, out-of-court restructuring, in-court restructuring, bankruptcy

or insolvency filing or similar transaction and (B) any other matters or actions as may be

necessary or advisable to effectuate any of the foregoing (including the selection and retention

of the Obligors’ professionals with respect to any such transaction), which Strategic

Process Committee shall be comprised solely of David Mack (and/or such other independent

director reasonably acceptable to the Majority Lenders) as of the Tenth Amendment Effective

Date; provided that the Board shall be permitted to appoint an additional independent

director to the Strategic Process Committee reasonably acceptable to the Majority Lenders

and that is not a member of the Board as of the Tenth Amendment Effective Date.

-7-

6. Representations

and Warranties. The Borrower hereby represents and warrants:

(a) None

of the execution, delivery and performance by the Borrower of this Amendment and the documents,

instruments and agreements executed in connection herewith (collectively, the “Amendment

Documents”) or performance under the Amendment Documents (i) requires

any Governmental Approval of, registration or filing with, or any other action by, any Governmental

Authority or any other Person, except for (x) such as have been obtained or made and are

in full force and effect and (y) filings and recordings in respect of perfecting or

recording the Liens created pursuant to the Security Documents, (ii) will violate (1) any

Law, (2) any Organic Document of the Borrower or any of its Subsidiaries or (3) any order

of any Governmental Authority, that in the case of clause (ii)(1) or clause (ii)(3),

individually or in the aggregate, would reasonably be expected to result in a Material Adverse

Effect, (iii) will violate or result in a default under any Material Agreement binding upon

the Borrower or any of its Subsidiaries that, individually or in the aggregate, would reasonably

be expected to result in a Material Adverse Effect or (iv) will result in the creation or

imposition of any Lien (other than Permitted Liens) on any asset of the Borrower or any of

its Subsidiaries.

(b) This

Amendment and the other Amendment Documents have been duly authorized by all necessary corporate

or other organizational action including, if required, approval by all necessary holders

of Equity Interests, and duly executed and delivered by the Borrower and constitutes, and

each of the Amendment Documents when executed and delivered by the Borrower will constitute,

a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in

accordance with its terms, except as such enforceability may be limited by (i) bankruptcy,

insolvency, reorganization, moratorium or similar laws of general applicability affecting

the enforcement of creditors’ rights and (ii) the application of general principles

of equity (regardless of whether such enforceability is considered in a proceeding in equity

or at law).

-8-

7. Release.

(a) In

consideration of this Amendment and agreements of the Administrative Agent and the Lenders

contained herein and for other good and valuable consideration, the receipt and sufficiency

of which is hereby acknowledged, the Borrower and the other Obligors (the “Releasing

Parties”), each on behalf of itself and its Subsidiaries and its and their

respective successors, assigns and other legal representatives hereby absolutely, unconditionally

and irrevocably releases, remises and forever discharges the Administrative Agent and the

Lenders and their respective present and former shareholders, affiliates, subsidiaries, divisions,

predecessors, directors, officers, attorneys, employees, agents and other representatives,

in each case solely in their capacities relative to the Lenders and not in any other capacity

such party may have relative to the Releasing Party (the Administrative Agent, each Lender

and all such other Persons being hereinafter referred to collectively as the “Releasees”

and individually as a “Releasee”), of and from all demands, actions,

causes of action, suits, covenants, contracts, controversies, agreements, promises, sums

of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims,

defenses, rights of set-off, demands and liabilities whatsoever of every name and nature,

known or unknown, suspected or unsuspected, both at law and in equity, which the Borrower,

the Obligors or any of their respective successors, assigns or other legal representatives

may now or hereafter own, hold, have or claim to have against the Releasees or any of them

for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises

at any time on or prior to the date hereof, for or on account of, or in relation to, or in

any way in connection with the Credit Agreement or any of the other Loan Documents or transactions

thereunder (any of the foregoing, a “Claim” and collectively, the

“Claims”). The Releasing Parties expressly acknowledges and agrees,

with respect to the Claims, that it waives, to the fullest extent permitted by applicable

law, any and all provisions, rights and benefits conferred by any applicable U.S. federal

or state law, or any principle of U.S. common law, that would otherwise limit a release or

discharge of any unknown Claims pursuant to this Section 7. Furthermore, the Releasing

Parties hereby absolutely, unconditionally and irrevocably covenants and agrees with and

in favor of each Releasee that it will not sue (at law, in equity, in any regulatory proceeding

or otherwise) any Releasee on the basis of any Claim released and/or discharged by the Releasing

Parties pursuant to this Section 7. The foregoing release, covenant and waivers of

this Section 7 shall survive and remain in full force and effect regardless of the

consummation of the transactions contemplated hereby, the repayment or prepayment of any

of the Loans, or the termination of the Credit Agreement, this Amendment, any other Loan

Document or any provision hereof or thereof.

(b) Each

Releasing Party understands, acknowledges and agrees that its release set forth above may

be pleaded as a full and complete defense and may be used as a basis for an injunction against

any action, suit or other proceeding which may be instituted, prosecuted or attempted in

breach of the provisions of such release.

-9-

Releasing Party agrees that no fact, event, circumstance, evidence or transaction which could

now be asserted or which may hereafter be discovered shall affect in any manner the final,

absolute and unconditional nature of the release set forth above.

8. Fees

and Expenses.

(a) The

Borrower agrees to pay within two (2) Business Days of written demand (a) all reasonable

and documented out-of-pocket fees, costs and expenses of the Administrative Agent and the

Lenders accrued prior to the date hereof and (b) all reasonable and documented out-of-pocket

fees, costs and expenses of the Administrative Agent and the Lenders incurred in connection

with the preparation, execution, delivery, and enforcement of (i) this Amendment, (ii) any

Amendment Documents, other Loan Documents or other post-closing amendments, agreements, arrangements

or documentation, (iii) any other instruments and documents to be delivered hereunder or

thereunder, in each case of clauses (a) and (b), including the fees and expenses of Sullivan

& Cromwell LLP (“S&C”), as outside counsel to Administrative

Agent and the Oaktree Lenders, and DLA Piper LLP (“DLA”), as outside

counsel to Q Boost Holding LLC, with respect thereto.

(b) Within

two (2) Business Days of the Amendment Effective Date, the Borrower shall have paid in full

all of the reasonable out-of-pocket costs, fees and expenses of the Administrative Agent

and the Lenders, including, the fees and expenses of S&C, as outside counsel to Administrative

Agent and the Oaktree Lenders and the fees and expenses of DLA, as outside counsel to Q Boost

Holding LLC to the extent invoiced on or prior to the date hereof.

9. Miscellaneous.

(a) Except

as otherwise expressly provided herein, (i) all provisions of the Credit Agreement and the

other Loan Documents remain in full force and effect and (ii) the execution, delivery and

effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy

of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the

Existing Credit Agreement or any of the Loan Documents. None of the Administrative Agent

or any Lender is under any obligation to enter into this Amendment. The entering into of

this Amendment by such parties shall not be deemed to limit or hinder any rights of any such

party under the Loan Documents, nor shall it be deemed to create or infer a course of dealing

between any such party, on the one hand, and the Borrower, on the other hand, with regard

to any provision of the Loan Documents. This Amendment shall constitute a Loan Document.

(b) This

Amendment may be executed in several counterparts and by each party on a separate counterpart,

each of which when so executed and delivered shall be an original, and all of which together

shall constitute one instrument. An executed facsimile or electronic copy of this Amendment

shall be effective for all purposes as an original hereof.

-10-

Amendment expresses the entire understanding of the parties with respect to the amendments

contemplated hereby. No prior negotiations or discussions shall limit, modify, or otherwise

affect the provisions hereof.

(d) This

Amendment and its contents shall be subject to the governing law, indemnification, venue,

service of process, waivers of jury trial and severability provisions of the Existing Credit

Agreement, mutatis mutandis.

[SIGNATURE PAGES FOLLOW]

-11-

IN WITNESS WHEREOF, the parties

hereto have caused this Amendment to be duly executed and delivered as of the day and year first above written.

BORROWER:

BIOXCEL THERAPEUTICS, INC.

By:

/s/ Vimal Mehta

Name:

Vimal Mehta

Title:

Chief Executive Officer

Address for Notices:

555 Long Wharf Drive, 12th Floor

New Haven, CT

06511

With a copy to (which shall not constitute notice):

Cooley LLP

3 Embarcadero Center 20th Floor

San Francisco, CA 94111-4004

Attn: Mischi a Marca

Email: gmamarca@cooley.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

ADMINISTRATIVE AGENT:

OAKTREE FUND ADMINISTRATION, LLC

By:

Oaktree Capital Management, L.P.

Its:

Managing Member

By:

/s/Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

LENDERS:

OAKTREE-TCDRS STRATEGIC CREDIT, LLC

By:

Oaktree Capital Management, L.P.

Its:

Manager

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE-FORREST MULTI-STRATEGY, LLC

By:

Oaktree Capital Management, L.P.

Its:

Manager

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP 125

Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE-TBMR STRATEGIC CREDIT FUND C, LLC

By:

Oaktree Capital Management, L.P.

Its:

Manager

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE-TBMR STRATEGIC CREDIT FUND F, LLC

By:

Oaktree Capital Management, L.P.

Its:

Manager

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE-TBMR STRATEGIC CREDIT FUND G, LLC

By:

Oaktree Capital Management, L.P.

Its:

Manager

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE-TSE 16 STRATEGIC CREDIT, LLC

By:

Oaktree Capital Management, L.P.

Its:

Manager

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P. 333

S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

INPRS STRATEGIC CREDIT HOLDINGS, LLC

By:

Oaktree Capital Management, L.P.

Its:

Manager

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071 Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE SPECIALTY LENDING CORPORATION

By:

Oaktree Fund Advisors, LLC

Its:

Investment Adviser

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE STRATEGIC CREDIT FUND

By:

Oaktree Fund Advisors, LLC

Its:

Investment Adviser

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE GCP FUND DELAWARE HOLDINGS, L.P.

By:

Oaktree Global Credit Plus Fund GP, L.P.

Its:

General Partner

By:

Oaktree Global Credit Plus Fund GP Ltd.

Its:

General Partner

By:

Oaktree Capital Management, L.P.

Its:

Director

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE DIVERSIFIED INCOME FUND INC.

By:

Oaktree Fund Advisors, LLC

Its:

Investment Adviser

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Managing Director

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE AZ STRATEGIC LENDING FUND, L.P.

By:

Oaktree AZ Strategic Lending Fund GP, L.P.

Its:

General Partner

By:

Oaktree Fund GP IIA, LLC

Its:

General Partner

By:

Oaktree Fund GP II, L.P.

Its:

Managing Member

By:

/s/ Mary Gallegly

Name:

Mary Gallegly

Title:

Authorized Signatory

By:

/s/ Jessica Dombroff

Name:

Jessica Dombroff

Title:

Authorized Signatory

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

Oaktree

LSL Fund Holdings EURRC S.à r.l.

26A, boulevard Royal L-2449

Luxembourg, Grand Duchy of Luxembourg

R.C.S Luxembourg Number: B269245

By:

/s/ Martin Eckel

Name:

Martin Eckel

Title:

Manager

By:

/s/ Flora Verrecchia

Name:

Flora Verrecchia

Title:

Manager

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

OAKTREE LSL FUND DELAWARE HOLDINGS EURRC, L.P.

By:

Oaktree Life Sciences Lending Fund GP, L.P.

Its:

General Partner

By:

Oaktree Life Sciences Lending Fund GP Ltd.

Its:

General Partner

By:

Oaktree Capital Management, L.P.

Its:

Director

By:

/s/ Mary Gallegly

Name: Mary Gallegly

Title: Managing Director

By:

/s/ Jessica Dombroff

Name: Jessica Dombroff

Title: Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: ******************

With a copy to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Aman Kumar

Email: ******************

With a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Email: blauta@sullcrom.com

[Signature Page to Tenth

Amendment to Credit Agreement and Guaranty]

Q BOOST HOLDING LLC

By:

/s/ Ahmed Nasser Al-Abdulghani

Name:

Ahmed Nasser Al-Abdulghani

Title:

Director

Address for Notices:

c/o Qatar Investment Authority

Ooredoo Tower (Building 14)

Al Dafna Street (Street 801)

Al Dafna (Zone 61) Doha, Qatar

A copy (which shall not constitute notice) shall also

be sent to:

General Counsel

Qatar Investment Authority

Ooredoo Tower (Building 14)

Al Dafna Street (Street 801)

Al Dafna (Zone 61)

Doha, Qatar

Email: notices.legal@qia.qa

A copy (which shall not constitute notice) shall also

be sent to:

Michael Dorf

DLA Piper LLP (US)

michael.dorf@us.dlapiper.com

+1 415 836 2580)

555 Mission Street

Suite 2400

San Francisco, CA 94105-2933

3203 Hanover Street, Suite 100

Palo Alto, CA 94304

[Signature

Page to Tenth Amendment to Credit Agreement and Guaranty]

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jul. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 06, 2026

Entity File Number

001-38410

Entity Registrant Name

BioXcel

Therapeutics, Inc.

Entity Central Index Key

0001720893

Entity Tax Identification Number

82-1386754

Entity Incorporation, State or Country Code

Entity Address, Address Line One

555

Long Wharf Drive

Entity Address, City or Town

New

Haven

Entity Address, State or Province

Entity Address, Postal Zip Code

06511

City Area Code

475

Local Phone Number

238-6837

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001

Trading Symbol

BTAI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration